AI & DIGITAL ONCOLOGY
Will AI reduce or increase inequities in cancer care?
While the use of artificial intelligence systems is expanding in oncology, ethical issues including biases introduced in care delivery and uneven access to technology raise concerns about whether some patients may be left behind
Pan-cancer AI model shows to predict 30-day mortality in patients with advanced cancer
In a study, a machine learning approach outperformed cancer-specific models and revealed universal biomarkers to guide end-of-life care decisions
Machine learning approach identifies the enzyme MMP2 as a key target for drug repurposing in advanced cervical cancer
Additional treatment targets and potentially repurposable agents were identified based on chemoradiotherapy response, which could now be explored for further validation.
LATEST NEWS
The updated ESMO-MCBS captures the evolving treatment landscape and patient priorities
The ESMO-Magnitude of Clinical Benefit Scale has been enhanced to address critical aspects of modern oncology trials, such as novel study designs, quality of life and long-term survival benefits
Patient-reported outcomes in dose-finding show value in oncology trial inclusion, but shared standards are needed
Findings from studies show that patient-centred evidence can inform decisions in early-phase cancer research
Subcutaneous pembrolizumab demonstrates noninferiority to intravenous administration
Phase III data in metastatic NSCLC support an alternative route of administering immunotherapy, which may have an impact on patients’ preferences and cancer care costs
OPINIONS
Next-generation CAR-T cells are in the pipeline
Philippe Cassier
Target-led treatments for lung cancer – are they moving to the next level?
Tony SK Mok
Technology integration and access to eligible patients underpin the growth of early-phase trials in Asia Pacific
Lilian L. Siu
ctDNA and RNA-based tests are expanding colorectal cancer screening options
Frank A. Sinicrope
Decoding genomic and transcriptomic signatures in colorectal cancer – next steps?
Federica Di Nicolantonio
OPINIONS
Next-generation CAR-T cells are in the pipeline
Philippe Cassier
Target-led treatments for lung cancer – are they moving to the next level?
Tony SK Mok
Technology integration and access to eligible patients underpin the growth of early-phase trials in Asia Pacific
Lilian L. Siu
ctDNA and RNA-based tests are expanding colorectal cancer screening options
Frank A. Sinicrope
Decoding genomic and transcriptomic signatures in colorectal cancer – next steps?
Federica Di Nicolantonio